Temozolomide and unusual indications: Review of literature
Authors:
- Zuzana TatarZTZuzana Tatar
- Emilie ThivatETEmilie Thivat
- Eloise PlanchatEPEloise Planchat
- Pierre GimberguesPGPierre Gimbergues
- Emilie GadeaEGEmilie Gadea
- Catherine AbrialCACatherine Abrial
- Xavier DurandoXDXavier Durando
- 1 April 2013
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 39 (2) , 125-135
Abstract
No abstract availableKeywords
This publication has 120 references indexed in Scilit:
- Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)European Journal of Nuclear Medicine and Molecular Imaging, 2011
- New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?Current Opinion in Oncology, 2010
- Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumorPituitary, 2009
- The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guidelineJournal of Neuro-Oncology, 2009
- Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II studyAnnals of Oncology, 2009
- A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastasesJournal of Neuro-Oncology, 2007
- RPA classification has prognostic significance for surgically resected single brain metastasisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO studyAnnals of Oncology, 2006
- Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG)Annals of Oncology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005